Table 1 Demographics
From: Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States
Characteristic | All patients (N = 172) |
|---|---|
Gender, n (%) | |
Female | 144 (84) |
Male | 27 (16) |
Age in years, mean (SD) | 46.0 (12.7) |
Mean follow-up in months, mean (SD) | 12.8 (4.8) |
Fremanezumab dosing, n (%) | |
Monthly | 168 (98) |
Quarterly | 3 (2) |
Ordering physician, n (%) | |
Neurology | 158 (92) |
Family medicine | 8 (5) |
Internal medicine | 3 (2) |
Pain medicine | 1 (1) |
Other | 2 (1) |